Table 2.
Percentage of Trials Achieving Remission and Corticosteroid-free Remission During 26- and 52-Week Follow-up Periods
| OUTCOME | DURATION OF FOLLOW-UP | INITIATOR TRIALS | NON-INITIATOR TRIALS | ||
|---|---|---|---|---|---|
| % ACHIEVING OUTCOME (95% CI) | |||||
| UNADJUSTED | |||||
| Clinical remission | 26 weeks | 54.4 | (47.7–61.1) | 41.2 | (38.2–44.2) |
| 52 weeks | 66.6 | (60.3–72.8) | 56.2 | (53.2–59.3) | |
| Corticosteroid-free remission | 26 weeks | 47.3 | (40.6–53.9) | 31.2 | (28.4–34.0) |
| 52 weeks | 60.1 | (53.7–66.5) | 47.5 | (44.5–50.5) | |
| ADJUSTED | |||||
| Clinical remission | 26 weeks | 54.8 | (47.2–62.4) | 40.7 | (36.5–45.0) |
| 52 weeks | 67.3 | (60.1–74.4) | 55.6 | (51.1–60.1) | |
| Corticosteroid-free remission | 26 weeks | 45.6 | (38.1–53.1) | 30.8 | (26.8–34.7) |
| 52 weeks | 58.8 | (51.5–66.2) | 47.0 | (42.5–51.5) | |
Note: Proportions were adjusted for patient age, gender, and race, disease location, duration, and phenotype, and concurrent medications, all measured at baseline of the trial. Adapted from Forrest and colleagues.44